SOUTHWEST ONCOLOGY GROUP

西南肿瘤集团

• 批准号: 6854994
• 负责人: LAWRENCE E FLAHERTY
• 金额: $ 8.04万
• 依托单位: WAYNE STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-01-01 至 2004-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6854994
• 关键词: antineoplastics; bleomycin; bone marrow transplantation; brain neoplasms; breast neoplasms; cancer information system; cancer prevention; cancer registry /resource; cis platinum compound; clinical research; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; doxorubicin; drug resistance; female reproductive system neoplasm; fludarabine; gastrointestinal neoplasms; head /neck neoplasm; hormone therapy; human subject; human therapy evaluation; ifosfamide; leukemia; lung neoplasms; lymphoma; meeting /conference /symposium; melanoma; multiple myeloma; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; oncology nursing; paclitaxel; pancreas neoplasms; pathology; prognosis; prostate neoplasms; quality of life; sarcoma; tamoxifen; tissue resource /registry; urinary tract neoplasms; women' s health

Description (Adapted from the applicant's abstract): Wayne State University (WSU) has been an active institutional member of the Southwest Oncology Group for over 25 years, enrolling over 4500 patients onto clinical trials. Over these years, their faculty have played an important role in support of SWOG, by providing leadership in the administrative and scientific functions of SWOG, and also by meeting and exceeding patient accrual goals in a continuous and consistent manner. Thus, WSU has remained in the first quartile of institution's performance evaluation conducted by SWOG in each of the last five years. The clinical research program in cancer at WSU has been organized along the lines of multidisciplinary disease oriented studies and in a manner which resembles the organ committee orientation of SWOG. Thus, their faculty's representation in scientific SWOG committees is constituted by individuals with expertise and commitment towards those areas of research. Accordingly, the translation of ideas into SWOG studies as well as the incorporation of SWOG studies and those of NCI designated high priority trials into WSU treatment priorities, are easily facilitated. In addition, the demographics of their region and the commitment of investigators to make clinical trials available to all patients, is clearly identified in their recruitment of minorities (33 percent) and women (46 percent) into SWOG clinical trials. The SWOG membership in WSU and the diversity of disciplinary involvement by their faculty has continued to grow over the years. To date, 87 WSU members are currently serving on 38 committees. Similarly, 60 SWOG studies list a WSU member as a study chairman or as study coordinator since the last competing application was submitted. Dr. Lawrence Flaherty, a SWOG member since 1986 and Vice-Chairman of the SWOG Melanoma Committee, becomes the Principal Investigator of this competing renewal at the departure of Dr. Manuel Valdivieso for another institution. He will maintain the prominence of WSU as a SWOG member institution.

描述（改编自申请人摘要）：韦恩州立大学